We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Jul 20
The two investigational vaccine candidates, BNT162b1 and BNT162b2, are part of the Pfizer and BioNTech’s BNT162 mRNA-based vaccine…
13 Jul 20
The trial initially enrolled 18 volunteers, for whom the Covid-19 vaccine was dosed on 18 June 2020 and…
09 Jul 20
Lynparza is an advanced PARP inhibitor and a targeted treatment designed to block the DNA damage response (DDR)…
08 Jul 20
The approval indicated the drug for uncontrolled asthma in patients who experienced one or more asthma exacerbations in…
06 Jul 20
The conditional marketing authorisation was granted based on the US National Institute of Allergy and Infectious Diseases’ global…
03 Jul 20
In the Phase 3 BRIGHTE trial, 60% of heavily treatment-experienced adults receiving Rukobia with an optimised background therapy…
03 Jul 20
The EC approval is based on the Phase 3 CREDENCE trial, which was stopped early after a planned…
02 Jul 20
Novartis has reached a settlement with the US Attorney’s Office for the Southern District of New York, the…
02 Jul 20
The Ebola vaccine regimen has been developed by leveraging Janssen’s AdVac technology, and Bavarian Nordic’s MVA-BN technology
01 Jul 20
BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody, co-developed and co-commercialised by Pfizer and EMD Serono